Pfizer (PFE) shares are up 2.01% to $25.64 as of 11:17 am on Friday, rising from the previous close of $25.13. The stock's upward movement today is primarily driven by the announcement of a strategic collaboration with Zai Lab to commercialize XACDURO, a new antibacterial drug, in mainland China. This partnership, which grants Pfizer exclusive rights to commercialize the drug, aims to leverage Pfizer's commercial infrastructure to enhance patient access to XACDURO, a treatment for carbapenem-resistant Acinetobacter baumannii. The collaboration is set to run until November 2028, potentially boosting Pfizer's presence in the Chinese market and addressing the growing issue of drug resistance.